Ensor CR, Iasella CJ, Harrigan (Zhang) KM, Morrell MR, Moore CA, Shigemura N, Zeevi A, McDyer JF, Venkataramanan R. Increasing tacrolimus time-in-therapeutic range is associated with superior one-year outcomes in lung transplant recipients. Am J Transplant. 2018 Jun;18(6):1527-33. doi: 10.1111/ajt.14723
Gallego R, Codony-Servat J, Garcia-Albeniz X, Carcereny E, Longaron R, Oliveras A, Tosca M, Auge JM, Gascon P, Maurel J. Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer. Endocr Relat Cancer. 2009 Mar;16(1):311-7. doi: 10.1677/ERC-08-0250
Michels KB, Rothman KJ. Update on unethical use of placebos in randomised trials. Bioethics. 2003 Apr;17(2):188-204.
Rivero E, Varas-Lorenzo C, Maguire AR, Eisen HJ, Pedersen TR, Nashan B, Elkammas E. 10-Year predicted probability of coronary heart disease in renal transplant recipients treated with everolimus or mmf. Poster presented at the American Transplant Congress; April 2002. Washington, DC. [abstract] Am J Transplant. 2002; 2(Suppl 3):418.
Palka P, Lange A, Wright RA, Starkey IR, Fleming AD, Bouki KP, Sutherland GR, Shaw TRD, Fox KAA. Myocardial velocity gradient measured throughout the cardiac cycle in dilated cardiomyopathy hearts — a potential new parameter of systolic and diastolic myocardial function by Doppler myocardial imaging. European journal of ultrasound. 1997 Jun 1;5(3):141-54. doi: 10.1016/S0929-8266(97)00014-1
Hoskins PR, Fleming A, Stonebridge PA, Allan PL, Cameron D. Scan-plane vector maps and secondary flow motions in arteries. European journal of ultrasound. 1994 Apr 1;1(2):159-69.